Otamixaban

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Otamixaban
Accession Number
DB06635
Type
Small Molecule
Groups
Investigational
Description

Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

Structure
Thumb
Synonyms
Not Available
External IDs
FXV-673 / RPR-130673 / RPR130673 / XRP-0673 / XRP0673
Product Ingredients
IngredientUNIICASInChI Key
Otamixaban HydrochlorideWL9J31M2HI409081-12-5ROKCPUOLRIBSQQ-BYYQELCVSA-N
Categories
UNII
S173RED00L
CAS number
193153-04-7
Weight
Average: 446.4983
Monoisotopic: 446.19540534
Chemical Formula
C25H26N4O4
InChI Key
PFGVNLZDWRZPJW-OPAMFIHVSA-N
InChI
InChI=1S/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)/t16-,22-/m1/s1
IUPAC Name
4-(4-{[(2R,3R)-3-[(3-carbamimidoylphenyl)methyl]-4-methoxy-4-oxobutan-2-yl]carbamoyl}phenyl)pyridin-1-ium-1-olate
SMILES
COC(=O)[[email protected]](CC1=CC(=CC=C1)C(N)=N)[[email protected]@H](C)NC(=O)C1=CC=C(C=C1)C1=CC=[N+]([O-])C=C1

Pharmacology

Indication

Investigated for use/treatment in thrombosis.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UCoagulation factor XNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the anticoagulant activities of Otamixaban.Investigational
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Otamixaban.Approved, Investigational
AbciximabAbciximab may increase the anticoagulant activities of Otamixaban.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Otamixaban.Approved, Investigational
AcemetacinThe risk or severity of bleeding can be increased when Otamixaban is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Otamixaban.Approved, Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Otamixaban.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Otamixaban.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Otamixaban.Approved, Withdrawn
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Otamixaban.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Otamixaban.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Otamixaban.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Otamixaban.Approved, Illicit, Investigational
AlprostadilAlprostadil may increase the anticoagulant activities of Otamixaban.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Otamixaban.Approved
AltrenogestThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Altrenogest.Vet Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Otamixaban.Experimental, Investigational
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Otamixaban.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Otamixaban.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Otamixaban.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Otamixaban.Approved
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Otamixaban.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Otamixaban.Approved
AncrodAncrod may increase the anticoagulant activities of Otamixaban.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Otamixaban.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Otamixaban.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Otamixaban.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Otamixaban.Approved, Investigational
Antithrombin III humanOtamixaban may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Otamixaban.Approved
ApocyninApocynin may increase the anticoagulant activities of Otamixaban.Investigational
ApremilastApremilast may increase the anticoagulant activities of Otamixaban.Approved, Investigational
ArdeparinArdeparin may increase the anticoagulant activities of Otamixaban.Approved, Investigational, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Otamixaban.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Otamixaban.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Otamixaban.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Otamixaban.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Otamixaban is combined with Azficel-T.Approved, Investigational
BalsalazideBalsalazide may increase the anticoagulant activities of Otamixaban.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Otamixaban.Experimental
BecaplerminBecaplermin may increase the anticoagulant activities of Otamixaban.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Otamixaban.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Otamixaban.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Otamixaban.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Otamixaban.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Otamixaban.Approved
BeraprostBeraprost may increase the anticoagulant activities of Otamixaban.Investigational
BevoniumBevonium may increase the anticoagulant activities of Otamixaban.Experimental
BivalirudinBivalirudin may increase the anticoagulant activities of Otamixaban.Approved, Investigational
BoceprevirThe serum concentration of Otamixaban can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BrinaseBrinase may increase the anticoagulant activities of Otamixaban.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Otamixaban.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Otamixaban.Approved, Investigational
BucillamineBucillamine may increase the anticoagulant activities of Otamixaban.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Otamixaban.Approved, Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Otamixaban.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Otamixaban.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Otamixaban.Investigational
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Otamixaban.Approved
CangrelorCangrelor may increase the anticoagulant activities of Otamixaban.Approved
CaplacizumabCaplacizumab may increase the anticoagulant activities of Otamixaban.Investigational
CarbamazepineThe metabolism of Otamixaban can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Otamixaban.Experimental, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Otamixaban.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Otamixaban.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Otamixaban.Approved, Investigational
CertoparinOtamixaban may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineChloroquine may increase the anticoagulant activities of Otamixaban.Approved, Investigational, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Otamixaban.Investigational, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Otamixaban.Approved
CilostazolCilostazol may increase the anticoagulant activities of Otamixaban.Approved, Investigational
Citric AcidCitric Acid may increase the anticoagulant activities of Otamixaban.Approved, Nutraceutical, Vet Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Otamixaban.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Otamixaban.Approved, Investigational, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Otamixaban.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Otamixaban.Approved
CloricromenCloricromen may increase the anticoagulant activities of Otamixaban.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Otamixaban.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Otamixaban is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Otamixaban.Approved
CurcuminCurcumin may increase the anticoagulant activities of Otamixaban.Approved, Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Otamixaban.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Otamixaban is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Otamixaban.Approved, Investigational, Vet Approved
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Otamixaban.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Otamixaban.Experimental
DalteparinOtamixaban may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidOtamixaban may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanOtamixaban may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Otamixaban.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Otamixaban is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Otamixaban.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Otamixaban.Approved
DemegestoneThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Demegestone.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Otamixaban is combined with Deoxycholic Acid.Approved
DersalazineDersalazine may increase the anticoagulant activities of Otamixaban.Investigational
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Otamixaban.Approved, Investigational
DesirudinOtamixaban may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Otamixaban.Investigational
DesogestrelThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Desogestrel.Approved
DextranOtamixaban may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Otamixaban.Experimental
DiclofenacDiclofenac may increase the anticoagulant activities of Otamixaban.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Otamixaban.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Otamixaban.Approved, Investigational
DienogestThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Otamixaban.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Otamixaban.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Otamixaban.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Otamixaban.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Otamixaban.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Otamixaban.Approved, Investigational
DiphenadioneDiphenadione may increase the anticoagulant activities of Otamixaban.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Otamixaban.Approved
DitazoleDitazole may increase the anticoagulant activities of Otamixaban.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Otamixaban.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Otamixaban.Approved, Investigational
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Otamixaban.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Otamixaban.Withdrawn
DuvelisibDuvelisib may increase the anticoagulant activities of Otamixaban.Investigational
DydrogesteroneThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Otamixaban.Approved
E-6201E-6201 may increase the anticoagulant activities of Otamixaban.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Otamixaban.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Otamixaban.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Otamixaban.Approved, Investigational
EnoxaparinEnoxaparin may increase the anticoagulant activities of Otamixaban.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Otamixaban.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Otamixaban.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Otamixaban.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Otamixaban.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Otamixaban.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Otamixaban.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Otamixaban.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Otamixaban.Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Otamixaban.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Otamixaban.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Otamixaban.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Otamixaban.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Otamixaban.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may decrease the anticoagulant activities of Otamixaban.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may decrease the anticoagulant activities of Otamixaban.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may decrease the anticoagulant activities of Otamixaban.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Otamixaban.Approved, Investigational
EstriolEstriol may decrease the anticoagulant activities of Otamixaban.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Otamixaban.Approved
EstroneEstrone may decrease the anticoagulant activities of Otamixaban.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Otamixaban.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Otamixaban.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Otamixaban.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Otamixaban.Approved
Ethyl biscoumacetateOtamixaban may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthynodiolThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Ethynodiol.Experimental
EtodolacEtodolac may increase the anticoagulant activities of Otamixaban.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Otamixaban.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Otamixaban.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Otamixaban.Approved
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Otamixaban.Approved, Investigational
ExisulindExisulind may increase the anticoagulant activities of Otamixaban.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Otamixaban.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Otamixaban.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Otamixaban.Approved
FentiazacFentiazac may increase the anticoagulant activities of Otamixaban.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Otamixaban.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Otamixaban.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Otamixaban.Investigational
FloctafenineFloctafenine may increase the anticoagulant activities of Otamixaban.Approved, Withdrawn
FluindioneOtamixaban may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunixinFlunixin may increase the anticoagulant activities of Otamixaban.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Otamixaban.Experimental
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Otamixaban.Approved, Investigational
FondaparinuxOtamixaban may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Otamixaban.Approved, Investigational
GabexateOtamixaban may increase the anticoagulant activities of Gabexate.Investigational
GarlicThe serum concentration of Otamixaban can be decreased when it is combined with Garlic.Approved
GenisteinGenistein may decrease the anticoagulant activities of Otamixaban.Investigational
GestodeneThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Gestrinone.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Otamixaban.Experimental
HeminHemin may increase the anticoagulant activities of Otamixaban.Approved, Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Otamixaban.Experimental
HeparinHeparin may increase the anticoagulant activities of Otamixaban.Approved, Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Otamixaban.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Otamixaban.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Otamixaban.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Otamixaban is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Otamixaban.Approved
IbudilastIbudilast may increase the anticoagulant activities of Otamixaban.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Otamixaban.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Otamixaban.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Otamixaban.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Otamixaban.Approved, Investigational, Nutraceutical
IdraparinuxIdraparinux may increase the anticoagulant activities of Otamixaban.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Otamixaban.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Otamixaban.Investigational
IloprostIloprost may increase the anticoagulant activities of Otamixaban.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Otamixaban.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Otamixaban.Approved
IndobufenIndobufen may increase the anticoagulant activities of Otamixaban.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Otamixaban.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Otamixaban.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Otamixaban.Experimental
IsoxicamIsoxicam may increase the anticoagulant activities of Otamixaban.Withdrawn
KebuzoneKebuzone may increase the anticoagulant activities of Otamixaban.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Otamixaban.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Otamixaban.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Otamixaban.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Otamixaban.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Otamixaban.Approved
LetaxabanOtamixaban may increase the anticoagulant activities of Letaxaban.Investigational
LevonorgestrelThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Otamixaban.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Otamixaban.Experimental
LisofyllineLisofylline may increase the anticoagulant activities of Otamixaban.Investigational
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Otamixaban.Experimental
LonazolacLonazolac may increase the anticoagulant activities of Otamixaban.Experimental
LornoxicamLornoxicam may increase the anticoagulant activities of Otamixaban.Approved, Investigational
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Otamixaban.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Otamixaban.Approved, Investigational
LumiracoxibLumiracoxib may increase the anticoagulant activities of Otamixaban.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Otamixaban.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Otamixaban.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Otamixaban.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Otamixaban.Approved
Megestrol acetateThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MelagatranOtamixaban may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamMeloxicam may increase the anticoagulant activities of Otamixaban.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Otamixaban.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Otamixaban.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Otamixaban.Approved, Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Otamixaban.Experimental
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Otamixaban.Approved, Vet Approved
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Otamixaban.Approved
MethylestrenoloneThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Methylestrenolone.Experimental
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Otamixaban.Approved, Illicit
MilrinoneMilrinone may increase the anticoagulant activities of Otamixaban.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Otamixaban.Approved
MizoribineMizoribine may increase the anticoagulant activities of Otamixaban.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Otamixaban.Experimental
MoxestrolMoxestrol may decrease the anticoagulant activities of Otamixaban.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Otamixaban.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Otamixaban.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Otamixaban.Approved
NadroparinOtamixaban may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatNafamostat may increase the anticoagulant activities of Otamixaban.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Otamixaban.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Otamixaban.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Otamixaban.Approved, Vet Approved
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Otamixaban.Approved, Withdrawn
NepafenacNepafenac may increase the anticoagulant activities of Otamixaban.Approved, Investigational
NifenazoneNifenazone may increase the anticoagulant activities of Otamixaban.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Otamixaban.Approved
NimesulideNimesulide may increase the anticoagulant activities of Otamixaban.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Otamixaban is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Otamixaban.Investigational
NomegestrolThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Norgestrienone.Experimental
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Otamixaban.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Otamixaban is combined with Obinutuzumab.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Otamixaban.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Otamixaban.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Otamixaban is combined with Omacetaxine mepesuccinate.Approved, Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Otamixaban.Approved, Nutraceutical
Omega-3-carboxylic acidsThe therapeutic efficacy of Otamixaban can be increased when used in combination with Omega-3-carboxylic acids.Approved, Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Otamixaban.Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Otamixaban.Vet Approved
OxaprozinOxaprozin may increase the anticoagulant activities of Otamixaban.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Otamixaban.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Otamixaban.Investigational
ParecoxibParecoxib may increase the anticoagulant activities of Otamixaban.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Otamixaban.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Otamixaban.Approved, Investigational
Pentaerythritol TetranitratePentaerythritol Tetranitrate may increase the anticoagulant activities of Otamixaban.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Otamixaban.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Otamixaban.Approved, Investigational
PethidineThe risk or severity of adverse effects can be increased when Otamixaban is combined with Pethidine.Approved
PhenindionePhenindione may increase the anticoagulant activities of Otamixaban.Approved, Investigational
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Otamixaban.Approved, Investigational
Phenyl aminosalicylatePhenyl aminosalicylate may increase the anticoagulant activities of Otamixaban.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Otamixaban.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Otamixaban.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Otamixaban.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Otamixaban.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Otamixaban.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Otamixaban.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Otamixaban.Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Otamixaban.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Otamixaban.Approved
ProgesteroneThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Otamixaban.Experimental
PromegestoneThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Otamixaban.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Otamixaban.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Otamixaban.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Otamixaban.Experimental
Protein COtamixaban may increase the anticoagulant activities of Protein C.Approved
Protein S humanOtamixaban may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeOtamixaban may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Otamixaban.Approved
PTC299PTC299 may increase the anticoagulant activities of Otamixaban.Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Otamixaban.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Otamixaban.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Otamixaban.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Otamixaban.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Otamixaban.Approved, Investigational
ReviparinOtamixaban may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Otamixaban.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Otamixaban.Approved
RivaroxabanOtamixaban may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Otamixaban.Approved, Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Otamixaban.Approved, Investigational
SalicylamideSalicylamide may increase the anticoagulant activities of Otamixaban.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Otamixaban.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Otamixaban.Approved
SarpogrelateSarpogrelate may increase the anticoagulant activities of Otamixaban.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Otamixaban.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Otamixaban.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Otamixaban.Approved
SemapimodSemapimod may increase the anticoagulant activities of Otamixaban.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Otamixaban.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Otamixaban.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Otamixaban.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Otamixaban.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Otamixaban.Approved
SRT501SRT501 may increase the anticoagulant activities of Otamixaban.Investigational
St. John's WortThe metabolism of Otamixaban can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StreptokinaseStreptokinase may increase the anticoagulant activities of Otamixaban.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Otamixaban.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Otamixaban.Approved
SulindacSulindac may increase the anticoagulant activities of Otamixaban.Approved, Investigational
SulodexideSulodexide may increase the anticoagulant activities of Otamixaban.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Otamixaban.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Otamixaban.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Otamixaban.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Otamixaban.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Otamixaban.Approved, Investigational
TarenflurbilTarenflurbil may increase the anticoagulant activities of Otamixaban.Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Otamixaban is combined with Temsirolimus.Approved
TenecteplaseTenecteplase may increase the anticoagulant activities of Otamixaban.Approved
TenidapTenidap may increase the anticoagulant activities of Otamixaban.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Otamixaban.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Otamixaban.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Otamixaban.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Otamixaban.Investigational
Testosterone cypionateThe therapeutic efficacy of Otamixaban can be increased when used in combination with Testosterone cypionate.Approved
Testosterone enanthateThe therapeutic efficacy of Otamixaban can be increased when used in combination with Testosterone enanthate.Approved
Testosterone undecanoateThe therapeutic efficacy of Otamixaban can be increased when used in combination with Testosterone undecanoate.Approved, Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Otamixaban.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Otamixaban.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Otamixaban.Approved
TiboloneTibolone may increase the anticoagulant activities of Otamixaban.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Otamixaban.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Otamixaban.Approved
TinoridineTinoridine may increase the anticoagulant activities of Otamixaban.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Otamixaban.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Otamixaban.Experimental
TipranavirThe serum concentration of Otamixaban can be decreased when it is combined with Tipranavir.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Otamixaban.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Otamixaban.Approved, Investigational
TolmetinTolmetin may increase the anticoagulant activities of Otamixaban.Approved
TositumomabThe risk or severity of adverse effects can be increased when Otamixaban is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Otamixaban.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Otamixaban.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Otamixaban.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Otamixaban.Approved, Investigational
TribenosideTribenoside may increase the anticoagulant activities of Otamixaban.Experimental
TriflusalTriflusal may increase the anticoagulant activities of Otamixaban.Approved, Investigational
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Otamixaban.Approved
TriptolideTriptolide may increase the anticoagulant activities of Otamixaban.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Otamixaban.Approved
TroxerutinOtamixaban may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Otamixaban.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Otamixaban.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Otamixaban.Approved, Investigational
VerapamilThe metabolism of Verapamil can be decreased when combined with Otamixaban.Approved
Vitamin EVitamin E may increase the anticoagulant activities of Otamixaban.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Otamixaban.Approved
WarfarinWarfarin may increase the anticoagulant activities of Otamixaban.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Otamixaban.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Otamixaban.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Otamixaban.Vet Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Otamixaban.Approved
ZileutonZileuton may increase the anticoagulant activities of Otamixaban.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Otamixaban.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5496659
ChemSpider
4593439
BindingDB
50114539
ChEMBL
CHEMBL46618
Wikipedia
Otamixaban

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceImpaired Renal Function1
2CompletedTreatmentAngioplasty, Transluminal, Percutaneous Coronary1
2CompletedTreatmentCoronary Heart Disease (CHD)1
3CompletedTreatmentAcute Coronary Syndromes (ACS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00202 mg/mLALOGPS
logP2.12ALOGPS
logP1.54ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)14.94ChemAxon
pKa (Strongest Basic)11.46ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area130.73 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity137.62 m3·mol-1ChemAxon
Polarizability48.06 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5326
Blood Brain Barrier+0.9199
Caco-2 permeable-0.591
P-glycoprotein substrateNon-substrate0.5454
P-glycoprotein inhibitor INon-inhibitor0.9186
P-glycoprotein inhibitor IINon-inhibitor0.7824
Renal organic cation transporterNon-inhibitor0.8502
CYP450 2C9 substrateNon-substrate0.7351
CYP450 2D6 substrateNon-substrate0.8129
CYP450 3A4 substrateNon-substrate0.5141
CYP450 1A2 substrateNon-inhibitor0.7534
CYP450 2C9 inhibitorNon-inhibitor0.6407
CYP450 2D6 inhibitorNon-inhibitor0.8638
CYP450 2C19 inhibitorNon-inhibitor0.6357
CYP450 3A4 inhibitorNon-inhibitor0.9066
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8028
Ames testNon AMES toxic0.5202
CarcinogenicityNon-carcinogens0.8271
BiodegradationNot ready biodegradable0.8529
Rat acute toxicity2.6725 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9975
hERG inhibition (predictor II)Non-inhibitor0.7187
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Phenylpyridines
Direct Parent
Phenylpyridines
Alternative Parents
Beta amino acids and derivatives / Benzamides / Benzoyl derivatives / Fatty acid esters / Pyridinium derivatives / Methyl esters / Heteroaromatic compounds / Secondary carboxylic acid amides / Azacyclic compounds / Monocarboxylic acids and derivatives
show 6 more
Substituents
4-phenylpyridine / Beta amino acid or derivatives / Benzamide / Benzoic acid or derivatives / Benzoyl / Fatty acid ester / Monocyclic benzene moiety / Fatty acyl / Benzenoid / Pyridinium
show 20 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Details
1. Coagulation factor X
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name
F10
Uniprot ID
P00742
Uniprot Name
Coagulation factor X
Molecular Weight
54731.255 Da
References
  1. Ahrens I, Peter K, Bode C: [Factor Xa-inhibition in interventional cardiology]. Hamostaseologie. 2007 Dec;27(5):328-32. [PubMed:18060241]
  2. Paccaly A, Ozoux ML, Chu V, Simcox K, Marks V, Freyburger G, Sibille M, Shukla U: Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor. Thromb Haemost. 2005 Dec;94(6):1156-63. [PubMed:16411387]

Drug created on March 19, 2008 10:42 / Updated on May 02, 2018 01:37